SOURCE: Atossa Genetics

Atossa Genetics

September 16, 2013 15:51 ET

Seattle-Based Atossa Genetics to Host Breast Health Fair

Event Provides Patients Opportunity to Be Tested With the ForeCYTE Breast Health Test to Detect Pre-Cancerous Breast Cancer Cells at the Earliest Stages of the Disease

SEATTLE, WA--(Marketwired - September 16, 2013) - Atossa Genetics Inc.

Atossa Genetics Inc., a Seattle-based healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer

Breast Health Fair 

Friday, September 27 from 2 to 6 p.m.
Saturday, September 28 from 10 a.m. to 5 p.m.

Holistique Medical Center
1899 116th Avenue Northeast
Bellevue, WA 98004

Atossa Genetics Inc., the Breast Health Company based in Seattle, is hosting a Breast Health Fair on Friday, September 27 and Saturday, September 28 during which patients will have the opportunity to be tested with the ForeCYTE Breast Health Test, which detects the beginnings of breast cancer years before it can show up on a mammogram. Healthcare providers will administer the test and medical experts will be onsite to discuss the latest innovations in breast cancer prevention.

The ForeCYTE Breast Health Test is a simple, quick, non-invasive test that can detect breast cancer cells at the earliest stages of disease. For women ages 50 to 73, the ForeCYTE Breast Health Test is intended to be used as a routine screen for breast cancer in addition to an annual mammogram. The test is also intended as an important tool for assessing and maintaining breast health in women between the ages of 18 and 49, for whom screening mammography is not currently recommended. For more information, visit or

Total out-of-pocket cost will be $125 or less for most patients. For estimated cost, call 1-888-403-2685.

To schedule an appointment, call 1-888-219-4625.

About Atossa Genetics Inc. [ATOS]:
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. ("NRLBH"), patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa, please visit For additional information on the ForeCYTE Breast Health Test and the National Reference Laboratory for Breast Health, please visit

Contact Information